Clinical Trials

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT04579679 2025-07-25

Open-Label Surufatinib in European Patients With NET

78 enrolled 20 charts

590 enrolled 58 charts 5 FDA

Neuroendocrine Tumors

NCT03037385 2025-05-31

ARROW

Phase 1/2 Completed

EndocrineGastrointestinalHead & NeckNETThoracic

Thyroid Cancer, Papillary, Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Carcinoma, Medullary, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 2a

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EndocrineGynecologicNETThoracic

139 enrolled 14 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

EndocrineGastrointestinalNET

42 enrolled 11 charts

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

DermatologicEndocrineGenitourinaryNET

337 enrolled 8 charts

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT03223428 2024-07-24

RELAX

Completed

223 enrolled 16 charts

Neuroendocrine Tumors, Serotonin Syndrome

NCT04644315 2023-08-07

ALpha-T

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

1 enrolled 5 charts

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Renal Cell, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT02592707 2023-07-19

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Phase 1/2 Terminated

40 enrolled 37 charts

Neuroendocrine Tumors

NCT03673943 2022-12-22

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

63 enrolled 8 charts

Neuroendocrine Tumors

NCT00774930 2022-10-14

ELECT

115 enrolled 17 charts

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT00842348 2022-10-12

NET729

89 enrolled 9 charts

Neuroendocrine Tumors

NCT01578239 2022-04-04

NETTER-1

231 enrolled 16 charts 2 FDA

Neuroendocrine Tumors

NCT01524783 2021-08-05

RADIANT-4

302 enrolled 16 charts

Neuroendocrine Tumors

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

34 enrolled 8 charts

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT02698410 2020-10-01

ATLANT

40 enrolled 17 charts

Neuroendocrine Tumors

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Phase 1 Completed

122 enrolled 19 charts

74 enrolled 10 charts 1 FDA

Neoplasms, Neuroendocrine Tumors

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Phase 2 Unknown

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

43 enrolled 12 charts

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT01525550 2019-07-30

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

EndocrineGastrointestinalNET

106 enrolled 26 charts

Adenoma, Carcinoma, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Phase 1 Terminated

29 enrolled 19 charts

EndocrineGenitourinaryNETThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT00688623 2019-01-25

RAMSETE/CDE16

73 enrolled 13 charts

Carcinoid Tumor, Carcinoma, Neuroendocrine Tumors

NCT01595009 2018-11-29

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

246 enrolled 16 charts

Neuroendocrine Tumors

NCT02299089 2017-12-15

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

12 enrolled 18 charts

Acromegaly, Neuroendocrine Tumors, Serotonin Syndrome

NCT02132468 2017-12-05

GI-NETorPNET

18 enrolled 10 charts

Carcinoid Tumor, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01374451 2016-12-20

COOPERATE-2

160 enrolled 17 charts

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Phase 1/2 Completed

24 enrolled 8 charts

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

62 enrolled 7 charts

BreastDermatologicEndocrineGastrointestinalGenitourinaryNETThoracic

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00753415 2015-03-17

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Phase 1 Completed

37 enrolled 10 charts

Adenocarcinoma, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Breast Diseases, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Genital Diseases, Male, Intestinal Neoplasms, Kidney Diseases, Kidney Neoplasms, Melanoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Prostatic Diseases, Prostatic Neoplasms, Skin Diseases, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Nevi and Melanomas, Neuroendocrine Tumors

NCT01121562 2014-06-30

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

12 enrolled 9 charts

Neuroendocrine Tumors

NCT00363051 2013-05-10

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy